Valuation: Cogent Biosciences, Inc.

Market Cap 6.68B 5.84B 5.39B 4.96B 9.36B 643B 9.57B 64.38B 25.32B 315B 25.08B 24.53B 1,084B P/E 2026 *
-17.1x
P/E 2027 * -47.3x
Enterprise Value 6.62B 5.79B 5.34B 4.92B 9.28B 638B 9.49B 63.85B 25.11B 312B 24.88B 24.33B 1,075B EV / Sales 2026 *
700x
EV / Sales 2027 * 19.2x
Free-Float
99.5%
Yield 2026 *
-
Yield 2027 * -
1 day+3.00%
1 week+0.54%
Current month+0.98%
1 month+16.07%
3 months+4.91%
6 months+0.36%
Current year+10.02%
1 week 37.04
Extreme 37.04
39.69
1 month 34.7
Extreme 34.7
40.89
Current year 30.87
Extreme 30.87
41.35
1 year 10.38
Extreme 10.38
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Free

Director

627 0.0004%
09/06/26 Free

Director

17,901 0.0105%
09/06/26 Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+3.00%+0.54%+220.33%+213.14% 6.68B
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.20%-2.31%+58.73%+186.73% 24.02B
Weighted average by Cap. -2.64%-2.27%+45.13%+146.02%

Financials

2026 *2027 *
Net sales 9.46M 8.27M 7.63M 7.03M 13.26M 911M 13.55M 91.19M 35.87M 446M 35.53M 34.75M 1.54B 345M 302M 278M 257M 484M 33.25B 495M 3.33B 1.31B 16.29B 1.3B 1.27B 56.07B
Net income -392M -342M -316M -291M -549M -37.71B -561M -3.77B -1.48B -18.47B -1.47B -1.44B -63.58B -134M -117M -108M -99.64M -188M -12.91B -192M -1.29B -508M -6.32B -503M -492M -21.77B
Net Debt -55.22M -48.26M -44.53M -41.04M -77.36M -5.32B -79.08M -532M -209M -2.6B -207M -203M -8.97B -63.88M -55.82M -51.51M -47.48M -89.49M -6.15B -91.48M -616M -242M -3.01B -240M -235M -10.37B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
17/07/26 $39.08 +3.00% 1,914,572
16/07/26 $37.94 -3.46% 2,576,186
15/07/26 $39.30 +2.05% 2,172,488
14/07/26 $38.51 +2.80% 2,076,049
13/07/26 $37.46 -3.63% 1,610,211
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
39.08USD
Average target price
54.25USD
Spread / Average Target
+38.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock